A Phase 1/2, Open-Label, Multicenter Study of GSK1363089G in Adult Subjects With Hepatocellular Carcinoma
Phase of Trial: Phase I/II
Latest Information Update: 17 May 2017
At a glance
- Drugs Foretinib (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 07 Nov 2016 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
- 21 Jul 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 02 Dec 2014 Planned End Date changed from 1 May 2014 to 1 Dec 2014 according to ClinicalTrials.gov record.